Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity

Abstract Background The failure of novel therapies effective in preclinical animal models largely reflects the fact that current models do not really mimic the pathological/therapeutic features of glioblastoma (GBM), in which the most effective temozolomide chemoradiotherapy (RT/TMZ) regimen can onl...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Feng Liu, Qian Zhou, Hai-feng Jiang, Ting-ting Zhang, Cheng Miao, Xiao-hong Xu, Jia-xing Wu, Song-lin Yin, Shi-jie Xu, Jing-yi Peng, Pan-pan Gao, Xuan Cao, Feng Pan, Ximiao He, Xiao Qian Chen
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2023-05-01
Serie:	Journal of Experimental & Clinical Cancer Research
Soggetti:	Piperlongumine Glioma Tumor microenvironment ROS generation/elimination Immunotherapy PD-1
Accesso online:	https://doi.org/10.1186/s13046-023-02686-1
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!